Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rheumatoid arthritis gene therapy - University of Pittsburgh

Drug Profile

Rheumatoid arthritis gene therapy - University of Pittsburgh

Alternative Names: IL-1Ra gene therapy

Latest Information Update: 21 Jan 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pittsburgh Medical Center
  • Class Antirheumatics; Gene therapies
  • Mechanism of Action Interleukin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 25 Feb 2002 A study has been added to the Rheumatoid arthritis pharmacodynamics sections
  • 16 May 2001 Phase-I clinical trials in Rheumatoid arthritis in USA (Intra-articular)
  • 29 Oct 1999 A study has been added to the adverse events and Rheumatoid arthritis pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top